<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    8885584
   </pmid>
   <datecreated>
    <year>
     1996
    </year>
    <month>
     12
    </month>
    <day>
     27
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1996
    </year>
    <month>
     12
    </month>
    <day>
     27
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     14
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0890-8567
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       35
      </volume>
      <issue>
       10
      </issue>
      <pubdate>
       <year>
        1996
       </year>
       <month>
        Oct
       </month>
      </pubdate>
     </journalissue>
     <title>
      Journal of the American Academy of Child and Adolescent Psychiatry
     </title>
     <isoabbreviation>
      J Am Acad Child Adolesc Psychiatry
     </isoabbreviation>
    </journal>
    <articletitle>
     Medication treatment strategies in the MTA Study: relevance to clinicians and researchers.
    </articletitle>
    <pagination>
     <medlinepgn>
      1304-13
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      Clinicians have difficulty applying drug research findings to clinical practice, because research protocols use methods different from those used in daily office practice settings.
     </abstracttext>
     <abstracttext label="METHOD" nlmcategory="METHODS">
      To design a medication protocol for a multisite clinical trial involving 576 children with attention-deficit hyperactivity disorder (ADHD) while maintaining relevance to clinical practice, investigators from the NIMH Collaborative Multisite Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA study) developed novel medication strategies. These were designed to work either in a monomodal or multimodal format and to ensure standard approaches are used across diverse sites. Each child randomized to medication (projected N = 288) is individually titrated to his or her "best" methylphenidate dose and has individual ADHD symptoms monitored. Decision rules were developed to guide "best dose" selection, dose changes, medication changes, the management of side effects, and integration with psychosocial treatments.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The MTA study uses a controlled method to standardize the identification of each child's "best" methylphenidate dose in a national, multisite cooperative treatment program. Although the titration protocol is complex, the study's individual dosing approach and algorithms for openly managing ADHD children's medication over time will be of interest to clinicians in office practice.
     </abstracttext>
    </abstract>
    <affiliation>
     Columbia University, New York, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Greenhill
      </lastname>
      <forename>
       L L
      </forename>
      <initials>
       LL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Abikoff
      </lastname>
      <forename>
       H B
      </forename>
      <initials>
       HB
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Arnold
      </lastname>
      <forename>
       L E
      </forename>
      <initials>
       LE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Cantwell
      </lastname>
      <forename>
       D P
      </forename>
      <initials>
       DP
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Conners
      </lastname>
      <forename>
       C K
      </forename>
      <initials>
       CK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Elliott
      </lastname>
      <forename>
       G
      </forename>
      <initials>
       G
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hechtman
      </lastname>
      <forename>
       L
      </forename>
      <initials>
       L
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hinshaw
      </lastname>
      <forename>
       S P
      </forename>
      <initials>
       SP
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hoza
      </lastname>
      <forename>
       B
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Jensen
      </lastname>
      <forename>
       P S
      </forename>
      <initials>
       PS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       March
      </lastname>
      <forename>
       J S
      </forename>
      <initials>
       JS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Newcorn
      </lastname>
      <forename>
       J
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Pelham
      </lastname>
      <forename>
       W E
      </forename>
      <initials>
       WE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Severe
      </lastname>
      <forename>
       J B
      </forename>
      <initials>
       JB
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Swanson
      </lastname>
      <forename>
       J M
      </forename>
      <initials>
       JM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Vitiello
      </lastname>
      <forename>
       B
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wells
      </lastname>
      <forename>
       K
      </forename>
      <initials>
       K
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <grantlist completeyn="N">
     <grant>
      <grantid>
       UO1 MH50440
      </grantid>
      <acronym>
       MH
      </acronym>
      <agency>
       NIMH NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
     <grant>
      <grantid>
       UO1 MH50447
      </grantid>
      <acronym>
       MH
      </acronym>
      <agency>
       NIMH NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
     <grant>
      <grantid>
       UO1 MH50461
      </grantid>
      <acronym>
       MH
      </acronym>
      <agency>
       NIMH NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
    </grantlist>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, U.S. Gov't, P.H.S.
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     J Am Acad Child Adolesc Psychiatry
    </medlineta>
    <nlmuniqueid>
     8704565
    </nlmuniqueid>
    <issnlinking>
     0890-8567
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Central Nervous System Stimulants
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      113-45-1
     </registrynumber>
     <nameofsubstance>
      Methylphenidate
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Algorithms
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Attention Deficit Disorder with Hyperactivity
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      psychology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Behavior Therapy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Central Nervous System Stimulants
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Combined Modality Therapy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dose-Response Relationship, Drug
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Methylphenidate
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Personality Assessment
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Research Design
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1996
     </year>
     <month>
      10
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1996
     </year>
     <month>
      10
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1996
     </year>
     <month>
      10
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     8885584
    </articleid>
    <articleid idtype="pii">
     S0890-8567(09)63633-9
    </articleid>
    <articleid idtype="doi">
     10.1097/00004583-199610000-00017
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

